Free Newsletter
Group launches $1B program to study cancer triggers
An international consortium of researchers has launched a billion-dollar effort to map every way that changes in DNA contributes to the development of tumors. The newly launched International Cancer Genome Consortium says that they hope to complete their work in less than 10 years as they ambitiously map out a project that is being described as the cancer equivalent of the Human Genome Project. Their goal is to make cancer therapy entirely personalized, where each patient's specific genetic makeup can be used to define the most effective therapy. And they will target the development of new cancer therapies to counter the genetic causes of cancer.
"In the past we have had piecemeal views of the cancer genome," said Professor Mike Stratton of the Wellcome Trust Sanger Institute. "With the advent of new faster DNA sequencing technologies, the ICGC now has set the hugely ambitious aim of fully sequencing thousands of cancer genomes to catalog all the changes in DNA, and obtain a complete picture of the abnormalities that lead to cancer with the aim of improving diagnosis and treatment."
- see the release
- check out the article in The Times
Related Article:
Biotechs use nanotech in pursuit of $100 sequencing bill
Genetics expert leaps into gene sequencing race
X Prize offers $10M for fast mapping
Comments
The ICGC is a nice thing to b done ..but then not all changes in the genome r necessary for cancer to manifest itself...every cancer has different specific mutations ...which one is most essential ?? wat is the order of these changes in the genome ..wil ICGC take care of giving all these details ???
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




